Novartis teams test combinations of targeted therapeutic agents to combat drug resistance in tumors.
Talk to any cancer researcher or doctor today and what you hear is wonder and hope.
Cambridge neighbors, NIBR and Harvard, further disrupt technology. Read how their alliance is accelerating drug discovery.
Novartis has joined forces with lymphoma experts in academia to hack into the genetics of a rare form of blood cancer known as mantle cell lymphoma (MCL).
When the average person thinks of cancer research, one word is likely to spring to mind: cure. Almost everyone who has ever lost a friend or loved one to the disease is hoping for a permanent, reliable cure for cancer. The sooner, the better.
Ricardo Dolmetsch was living the scientific dream by his mid-30s. Already a professor at Stanford University, he was running a successful lab, winning grants and receiving recognition for work in an area of neuroscience called calcium channel signaling. But then his son was diagnosed with autism.
Do answers to the mysteries of cancer lie hidden within the DNA of tumor cells? Researchers think so.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.